Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.ACST · Entity 7266 | Director · PRESIDENT & CEO | June 22, 2022 | June 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date June 22, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2032-06-22 | Direct | 560,000 |
Reported balance
After 2022-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 560,000 · Balance 560,000 F1: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant. F2: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant.
F2: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2022 Filed Jun 23, 2022 16:33 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 560,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001171843-22-004514 · ownership.xml · derivative · entry 1 D'Alvise Janelle · CIK 0001807412 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,000 Underlying: Class A Common Shares · 560,000 shares Expires 2032-06-22 F1 · derivative.exercise_price: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:18 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 655,500 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008006 · ownership.xml · derivative · entry 1 D'Alvise Janelle · CIK 0001807412 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,500 Underlying: Class A Common Shares · 655,500 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.